AXIOS July 9, 2024
Tina Reed

Two of the buzziest technology trends in health care — artificial intelligence and weight-loss drugs — appear to be converging as companies increasingly scope out the potential to capitalize on both.

Why it matters: Some companies tell Axios the explosive demand, outsized costs and wide range of potential of uses for GLP-1s — the category of drugs that includes diabetes drug Ozempic and its weight-loss counterpart Wegovy — make them the perfect test case for AI’s potential.

“With any hot space, there’s always a lot of noise. It’s unavoidable,” said Alexander Singh, founder of Alfie Health, an AI obesity care startup that was recently acquired by obesity care platform Knownwell.

  • He’s among those who argue there’s some true value...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Pharma / Biotech, Technology
New drug delivery method promises long-lasting glaucoma relief
Q&A: Gain Therapeutics CEO Discusses AI-Driven Drug Discovery, Strategic Growth Plans
A Covid Nasal Vaccine Update
Pharma Pulse 2/14/25: Building Confidence in CGT Innovation, The Power of PBMs and Biosimilars & more
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public

Share This Article